Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that 2 adalimumab biosimilars be treated as equivalent to the reference adalimumab, Humira, and be subject to substitution at the pharmacy level.
Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that 2 adalimumab biosimilars be treated as equivalent to the reference adalimumab, Humira, and be subject to substitution at the pharmacy level.
The products, Amgen’s Amgevita and Samsung Bioepis’ Hadlima, will be “a-flagged,” or given a listing that allows them to be substituted for Humira—or for one another—by a pharmacist for the indications that they share, although the prescribing physician retains the right to prevent substitution by requiring a prescription to be dispensed as written.
Read more about biosimilars in Australia.
In the case of Amgevita, which is approved for all indications of the reference product, a pharmacist could substitute Amgevita for Humira or Hadlima. In the case of Hadlima, which is only approved to treat rheumatoid arthritis (RA), Hadlima could be substituted by the pharmacist for either Humira or Amgevita to treat RA only.
Furthermore, the PBAC recommended that Australia’s “uptake drivers” be applied to adalimumab in the same way that they have been applied to etanercept and infliximab. The uptake drivers are policies that encouraging prescribing of biosimilars over branded drugs for new patients and that provide a faster and simpler preapproval process for patients to receive a biosimilar drug than a branded drug.
As part of the uptake driver process, the Australian government publishes fact sheets on the biosimilars, with separate documents made available to prescribers, pharmacists, and patients or their caregivers.
Australia’s approach to promoting biosimilar uptake through “a-flagging” biosimilars for substitution stands in contrast to the strategies used in the United States and Europe. In the United States, pharmacy-level substitution will only be permissible by law for products that gain the FDA’s designation of interchangeability (final guidance on which is yet to be published), and rules governing substitution will vary among US states according to local laws. In Europe, pharmacy-level substitution is, for the most part, forbidden; Estonia, France, Latvia, Poland, and Russia are notable exceptions.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.